• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by ImmunoPrecise Antibodies Ltd.

    7/30/24 1:57:45 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPA alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001715925
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    ImmunoPrecise Antibodies Ltd.
    Jurisdiction of Incorporation/Organization
    BRITISH COLUMBIA, CANADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    ImmunoPrecise Antibodies Ltd.
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8 6048060626

    3. Related Persons

    Last Name First Name Middle Name
    Bath Jennifer
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Levine Mitch
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Buyse Chris
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Springer Barry
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Witters Dirk
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Taylor Kristin
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Roodnik Ilse
    Street Address 1 Street Address 2
    3204 - 4464 Markham Street
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8Z 7X8
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
    X Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-07-16    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
    X Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Clear Street LLC 288933
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    4 World Trade Center, 150 Greenwich Stre 45th Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10007
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW JERSEY

    13. Offering and Sales Amounts

    Total Offering Amount $3,000,000 USD
    or    Indefinite
    Total Amount Sold $2,000,000 USD
    Total Remaining to be Sold $1,000,000 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $210,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    ImmunoPrecise Antibodies Ltd. Kristin Taylor Kristin Taylor CFO 2024-07-30

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $IPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPA

    DatePrice TargetRatingAnalyst
    12/2/2022$9.00Buy
    H.C. Wainwright
    10/25/2021$12.00Buy
    Benchmark
    10/25/2021$12.00Buy
    The Benchmark Company
    More analyst ratings

    $IPA
    SEC Filings

    View All

    SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

    6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

    9/3/25 9:21:16 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

    6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

    9/2/25 8:58:58 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

    6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

    8/27/25 9:49:34 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to "HYFT"

    An Evolution in Name, Structure, and Strategy Reflecting the Company's AI-Driven Platform and Bio-Native Discovery Vision ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announced a unification under a single corporate brand, MindWalk, and a change of its Nasdaq ticker symbol to HYFT. The new identity conveys the Company's evolution into a Bio-Native AI platform business built at the intersection of AI, multi-omics data, and advanced laboratory research. "Today is an evolutionary step forward," said Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk. "Inspired by Darwin'

    9/3/25 8:48:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

    ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025. Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Event Details: Conference: 27th Annual H.C. Wainwright Global Investment Conference Date: September 8-10th, 2025 Investors interested in scheduling a meeting with the IPA management team should contact their H.C. Wainwright representative or email [email protected] About ImmunoPrecise Antibodies Ltd.

    9/2/25 8:01:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

    Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology, the Company has updated that they are now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralizatio

    8/27/25 8:22:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

    H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

    12/2/22 8:15:24 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

    Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

    10/25/21 7:31:59 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

    The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

    10/25/21 7:28:32 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Financials

    Live finance-specific insights

    View All

    ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

    ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180

    7/29/25 8:28:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

    The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere

    7/16/25 8:05:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

    Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug disc

    3/28/25 8:01:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

    SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

    2/27/24 10:33:04 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ImmunoPrecise Antibodies Ltd. (Amendment)

    SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

    1/10/24 1:53:08 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

    SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

    1/10/24 1:33:21 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Leadership Updates

    Live Leadership Updates

    View All

    AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

    Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe" or the "Company"). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai™ platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bio's European footprint and adds advanced capabilities in antibody

    8/6/25 8:00:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

    ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve

    7/21/25 8:28:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

    ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded

    7/7/25 9:00:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care